Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

Inclusion Criteria: * A patient may be included in the study if the following conditions are present: 1. Male or female; 2. Age \> 18 years old; 3. Patients who match the criteria for indication of elective open aortic arch replacement or repair: 1. Total arch; 2. Non-total arch; 4. Patients who match the criteria for indication of elective complex aortic aneurysm repair has to respect the following conditions: a. Patients undergoing complex aortic aneurysm open reconstruction with a suprarenal clamp; i. thoracoabdominal aortic aneurysms Crawford extent I to IV ; ii. abdominal aortic aneurysms of juxtarenal, pararenal, or paravisceral type; b. For endovascular approach: i. patients with pararenal or thoracoabdominal aortic aneurysms Crawford extent I to IV and known stage III or IV of chronic kidney disease (CKD); ii. patients with pararenal or thoracoabdominal aortic aneurysms Crawford extent I to IV and solitary or single functioning kidney and known stage III or IV CKD; 5. Patients will be allowed to participate in concomitant endovascular aortic stent-graft trials and prospective cohort studies as long as these do not involve another investigational study drug. Exclusion Criteria: * Patients must be excluded from the study if any of the following conditions are true: 5.2.1 General Exclusion Criteria 1. Unwilling to comply with the follow-up schedule; 2. Inability or refusal to give informed consent by the patient or a legally authorized representative; 3. Pregnant or breastfeeding; 4. Subject who takes multivitamins containing vitamin B3 derivatives in a dose \> 200 mg/day; 5.2.2 Clinical / Laboratory Exclusion Criteria 5. Renal failure defined as eGFR\< 15 mL/min/1.73m2 6. Patients in permanent Renal Replacement Therapy; 7. Patients with chronic liver disease: Child-Pugh score class B and C; 5.2.3 Medication Exclusion Criteria 8. Patients in chemotherapy scheme; 9. Patients taking any immunosuppressant, except for corticosteroids; 10. Patients taking any of these well-known P-glycoprotein substrates: digoxin, fexofenadine, indinavir, sirolimus.